Handa Pharmaceuticals, Inc. (TPEX: 6620)
Taiwan
· Delayed Price · Currency is TWD 80.10
+1.80 (2.30%)
Sep 11, 2024, 2:30 PM CST
Handa Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 972.97 | 1,106 | 197.68 | 29.24 | 28.86 | 84.07 | Upgrade
|
| Revenue Growth (YoY) | 34.58% | 459.66% | 576.16% | 1.30% | -65.67% | -10.27% | Upgrade
|
| Cost of Revenue | 1.29 | 1.3 | 18.71 | 1.46 | 1.42 | 15.36 | Upgrade
|
| Gross Profit | 971.68 | 1,105 | 178.97 | 27.77 | 27.44 | 68.71 | Upgrade
|
| Selling, General & Admin | 99.73 | 104.87 | 87.31 | 72.67 | 70.87 | 99.26 | Upgrade
|
| Research & Development | 346.53 | 306.72 | 179.78 | 208.99 | 274.04 | 174.4 | Upgrade
|
| Operating Expenses | 446.26 | 411.59 | 267.09 | 281.66 | 344.92 | 273.65 | Upgrade
|
| Operating Income | 525.42 | 693.43 | -88.12 | -253.88 | -317.48 | -204.94 | Upgrade
|
| Interest Expense | -0.23 | -0.22 | -0.28 | -0.23 | -0.45 | -0.44 | Upgrade
|
| Interest & Investment Income | 45.98 | 18.16 | 0.5 | 0.29 | 2.99 | 7.06 | Upgrade
|
| Earnings From Equity Investments | 5.46 | 2.37 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 14.14 | 1.71 | 44.02 | -7.27 | -14.31 | -3.54 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.65 | 72.44 | 0.73 | 0.27 | 13.3 | -1.26 | Upgrade
|
| EBT Excluding Unusual Items | 587.13 | 787.88 | -43.15 | -260.82 | -315.95 | -203.11 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 4.61 | -0 | 0.02 | -0 | 0.01 | Upgrade
|
| Asset Writedown | - | - | - | - | -4.5 | - | Upgrade
|
| Pretax Income | 587.13 | 792.49 | -43.15 | -260.8 | -320.45 | -203.1 | Upgrade
|
| Income Tax Expense | 134.81 | 65.6 | -3.14 | -13.13 | -38.34 | -25.36 | Upgrade
|
| Net Income | 452.32 | 726.89 | -40.01 | -247.67 | -282.1 | -177.74 | Upgrade
|
| Net Income to Common | 452.32 | 726.89 | -40.01 | -247.67 | -282.1 | -177.74 | Upgrade
|
| Net Income Growth | -16.30% | - | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 140 | 134 | 126 | 118 | 116 | 110 | Upgrade
|
| Shares Outstanding (Diluted) | 140 | 135 | 126 | 118 | 116 | 110 | Upgrade
|
| Shares Change (YoY) | 7.81% | 7.29% | 6.65% | 1.87% | 5.35% | 4.89% | Upgrade
|
| EPS (Basic) | 3.24 | 5.41 | -0.32 | -2.10 | -2.44 | -1.62 | Upgrade
|
| EPS (Diluted) | 3.24 | 5.40 | -0.32 | -2.10 | -2.44 | -1.62 | Upgrade
|
| EPS Growth | -22.11% | - | - | - | - | - | Upgrade
|
| Free Cash Flow | 744.84 | 667.42 | -212.21 | -184.82 | -315.88 | -235.82 | Upgrade
|
| Free Cash Flow Per Share | 5.32 | 4.95 | -1.69 | -1.57 | -2.73 | -2.15 | Upgrade
|
| Dividend Per Share | 1.000 | 1.000 | - | - | - | - | Upgrade
|
| Gross Margin | 99.87% | 99.88% | 90.53% | 95.00% | 95.07% | 81.73% | Upgrade
|
| Operating Margin | 54.00% | 62.68% | -44.58% | -868.42% | -1100.10% | -243.77% | Upgrade
|
| Profit Margin | 46.49% | 65.70% | -20.24% | -847.17% | -977.53% | -211.42% | Upgrade
|
| Free Cash Flow Margin | 76.55% | 60.33% | -107.35% | -632.19% | -1094.57% | -280.51% | Upgrade
|
| EBITDA | 529.31 | 698.48 | -81.3 | -245.05 | -309.06 | -195.26 | Upgrade
|
| EBITDA Margin | 54.40% | 63.14% | -41.13% | - | - | -232.25% | Upgrade
|
| D&A For EBITDA | 3.89 | 5.06 | 6.82 | 8.83 | 8.42 | 9.68 | Upgrade
|
| EBIT | 525.42 | 693.43 | -88.12 | -253.88 | -317.48 | -204.94 | Upgrade
|
| EBIT Margin | 54.00% | 62.68% | -44.58% | - | - | -243.77% | Upgrade
|
| Effective Tax Rate | 22.96% | 8.28% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.